These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 33333252)

  • 21. Intravenous methylprednisolone with or without tocilizumab in patients with severe COVID-19 pneumonia requiring oxygen support: A prospective comparison.
    Hamed DM; Belhoul KM; Al Maazmi NA; Ghayoor F; Moin M; Al Suwaidi M; Narainen M; Makki M; AbdulRahman M
    J Infect Public Health; 2021 Aug; 14(8):985-989. PubMed ID: 34153729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tocilizumab in the Management of COVID-19: A Preliminary Report.
    Li M; Yoo EJ; Baram M; McArthur M; Skeehan C; Awsare B; George G; Summer R; Zurlo J; Jallo J; Roman J
    Am J Med Sci; 2021 Feb; 361(2):208-215. PubMed ID: 33358502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dosing and Administration Strategies of Tocilizumab in Patients With COVID-19: A Retrospective Cohort Analysis.
    Steuber TD; Rosandich T; Cadwallader T; Steil L; Belk M; Yendrapalli U; Hassoun A; Edwards J
    Ann Pharmacother; 2024 Apr; 58(4):391-397. PubMed ID: 37522616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tocilizumab and steroid treatment in patients with COVID-19 pneumonia.
    Mikulska M; Nicolini LA; Signori A; Di Biagio A; Sepulcri C; Russo C; Dettori S; Berruti M; Sormani MP; Giacobbe DR; Vena A; De Maria A; Dentone C; Taramasso L; Mirabella M; Magnasco L; Mora S; Delfino E; Toscanini F; Balletto E; Alessandrini AI; Baldi F; Briano F; Camera M; Dodi F; Ferrazin A; Labate L; Mazzarello G; Pincino R; Portunato F; Tutino S; Barisione E; Bruzzone B; Orsi A; Schenone E; Rosseti N; Sasso E; Da Rin G; Pelosi P; Beltramini S; Giacomini M; Icardi G; Gratarola A; Bassetti M
    PLoS One; 2020; 15(8):e0237831. PubMed ID: 32817707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tocilizumab for the Critically Ill With Severe COVID-19: A Community Hospital Case Series.
    McKenzie MG; Lee YM; Mathew J; Anderson M; Vo AT; Akinyele S; Narayanan M
    J Pharm Pract; 2022 Aug; 35(4):587-592. PubMed ID: 33736526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case-controlled study.
    Rojas-Marte G; Khalid M; Mukhtar O; Hashmi AT; Waheed MA; Ehrlich S; Aslam A; Siddiqui S; Agarwal C; Malyshev Y; Henriquez-Felipe C; Sharma D; Sharma S; Chukwuka N; Rodriguez DC; Alliu S; Le J; Shani J
    QJM; 2020 Aug; 113(8):546-550. PubMed ID: 32569363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delayed inflammation decrease is associated with mortality in Tocilizumab-treated critically ill SARS-CoV-2 patients: A retrospective matched-cohort analysis.
    Urbina T; Lavillegrand JR; Garnier M; Mekinian A; Pacanowski J; Mario N; Dumas G; Hariri G; Pilon A; Darrivère L; Fartoukh M; Guidet B; Maury E; Leblanc J; Chantran Y; Fain O; Lacombe K; Voiriot G; Ait-Oufella H
    Innate Immun; 2022 Jan; 28(1):3-10. PubMed ID: 35089113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tocilizumab in critically ill COVID-19 patients: An observational study.
    Mushtaq MZ; Mahmood SBZ; Almas A; Ather Wasti S; Ahsan Ali S
    Int Immunopharmacol; 2022 Jan; 102():108384. PubMed ID: 34838490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute respiratory distress syndrome due to COVID-19. Clinical and prognostic features from a medical Critical Care Unit in Valencia, Spain.
    Ramírez P; Gordón M; Martín-Cerezuela M; Villarreal E; Sancho E; Padrós M; Frasquet J; Leyva G; Molina I; Barrios M; Gimeno S; Castellanos Á
    Med Intensiva (Engl Ed); 2021; 45(1):27-34. PubMed ID: 32919796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India.
    Gokhale Y; Mehta R; Kulkarni U; Karnik N; Gokhale S; Sundar U; Chavan S; Kor A; Thakur S; Trivedi T; Kumar N; Baveja S; Wadal A; Kolte S; Deolankar A; Pednekar S; Kalekar L; Padiyar R; Londhe C; Darole P; Pol S; Gokhe SB; Padwal N; Pandey D; Yadav D; Joshi A; Badgujar H; Trivedi M; Shah P; Bhavsar P
    BMC Infect Dis; 2021 Mar; 21(1):241. PubMed ID: 33673818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of tocilizumab on intensive care patients with Covid-19 pneumonia, a retrospective cohort study.
    Küçük MP; Küçük AO; Pehlivanlar A; Mürtezaoğlu SA; Çoban K; Kılıç G; Ayçiçek O; Öztuna F; Bülbül Y; Özlü T
    Turk J Med Sci; 2022 Feb; 52(1):39-49. PubMed ID: 36161598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation of the Effects of Tocilizumab Use on Oxygen Parameters, Inflammatory Markers and Survival in Patients Diagnosed with COVID-19 in Intensive Care Unit].
    Yılmaz B; Doğan M; Ergut Sezer B
    Mikrobiyol Bul; 2023 Jan; 57(1):97-107. PubMed ID: 36636849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study.
    Ramiro S; Mostard RLM; Magro-Checa C; van Dongen CMP; Dormans T; Buijs J; Gronenschild M; de Kruif MD; van Haren EHJ; van Kraaij T; Leers MPG; Peeters R; Wong DR; Landewé RBM
    Ann Rheum Dis; 2020 Sep; 79(9):1143-1151. PubMed ID: 32719045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
    Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
    Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Use of High-Dose Corticosteroids Versus Low-Dose Corticosteroids With and Without Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.
    Katz A; Altshuler D; Papadopoulos J; Amoroso N; Goldenberg R; Tarras E; Krolikowski K; Hagedorn J; Fridman D; Chen XJC; Iturrate E; Brosnahan SB
    Ann Pharmacother; 2023 Jan; 57(1):5-15. PubMed ID: 35590468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study.
    Chilimuri S; Sun H; Alemam A; Kang KS; Lao P; Mantri N; Schiller L; Sharabun M; Shehi E; Tejada J; Yugay A; Nayudu SK
    J Clin Pharm Ther; 2021 Apr; 46(2):440-446. PubMed ID: 33098139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nebulised surfactant for the treatment of severe COVID-19 in adults (COV-Surf): A structured summary of a study protocol for a randomized controlled trial.
    Dushianthan A; Clark H; Madsen J; Mogg R; Matthews L; Berry L; de la Serna JB; Batchelor J; Brealey D; Hussell T; Porter J; Djukanovic R; Feelisch M; Postle A; Grocott MPW
    Trials; 2020 Dec; 21(1):1014. PubMed ID: 33302976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2.
    Petrak RM; Skorodin NC; Van Hise NW; Fliegelman RM; Pinsky J; Didwania V; Anderson M; Diaz M; Shah K; Chundi VV; Hines DW; Harting BP; Sidwha K; Yu B; Brune P; Owaisi A; Beezhold D; Kent J; Vais D; Han A; Gowda N; Sahgal N; Silverman J; Stake J; Nepomuceno J; Heddurshetti R
    Clin Transl Sci; 2021 Nov; 14(6):2146-2151. PubMed ID: 32918792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.